FDA declares the semaglutide shortage resolved
The declaration narrowed lawful compounding to the patient-specific 503A pathway and set the deadlines that reshaped the market.
FDA declared the national semaglutide shortage resolved in February 2025. Shortage status was what permitted compounding at scale, so its removal narrowed the lawful pathway sharply.
State-licensed pharmacies had until 22 April 2025 and outsourcing facilities until 22 May 2025. A district court declined to pause the deadlines.
What did not happen is the disappearance predicted at the time. Compounding for an identified patient against a valid prescription operates under a statutory pathway shortage status does not create.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.